Stay updated on GX-I7 and Pembrolizumab in R/R TNBC Clinical Trial
Sign up to get notified when there's something new on the GX-I7 and Pembrolizumab in R/R TNBC Clinical Trial page.

Latest updates to the GX-I7 and Pembrolizumab in R/R TNBC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe clinical trial record for the GX-I7 and pembrolizumab study in relapsed or refractory triple-negative breast cancer is displayed, with study design, eligibility, locations, and outcome details. The record indicates the study is completed and no longer recruiting.SummaryDifference47%

- Check17 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0. The page continues to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check24 days agoChange DetectedA site-wide NIH notice announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check31 days agoChange DetectedThe site revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check38 days agoChange DetectedThe site footer revision indicator changed from v3.7.0 to v3.7.1 while the page continued to display a 403 error.SummaryDifference0.2%

- Check52 days agoChange DetectedThe page now shows a 403 Forbidden response instead of the study details, indicating access restriction to the study record.SummaryDifference0.5%

Stay in the know with updates to GX-I7 and Pembrolizumab in R/R TNBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GX-I7 and Pembrolizumab in R/R TNBC Clinical Trial page.